2. Search Result
Search Result
Results for "

DIO.

" in MedChemExpress (MCE) Product Catalog:

49

Inhibitors & Agonists

3

Fluorescent Dye

3

Biochemical Assay Reagents

4

Peptides

8

Natural
Products

5

Isotope-Labeled Compounds

7

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-D0969
    DiO
    Maximum Cited Publications
    17 Publications Verification

    DiOC18(3); 3,3'-Dioctadecyloxacarbocyanine perchlorate

    		 Fluorescent Dye Others
    DiO is a long-chain carbocyanine dye. Carbocyanine dyes are widely used as Di to label cells, organelles, liposomes, viruses and lipoproteins .
    DiO
  • HY-RS03770
    DIO2 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    DIO2 Human Pre-designed siRNA Set A contains three designed siRNAs for DIO2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    DIO2 Human Pre-designed siRNA Set A
    DIO2 Human Pre-designed siRNA Set A
  • HY-RS03769
    DIO1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    DIO1 Human Pre-designed siRNA Set A contains three designed siRNAs for DIO1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    DIO1 Human Pre-designed siRNA Set A
    DIO1 Human Pre-designed siRNA Set A
  • HY-RS22137
    Dio3 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Dio3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Dio3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Dio3 Mouse Pre-designed siRNA Set A
    Dio3 Mouse Pre-designed siRNA Set A
  • HY-RS28658
    Dio3 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others
    Dio3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Dio3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Dio3 Rat Pre-designed siRNA Set A
    Dio3 Rat Pre-designed siRNA Set A
  • HY-RS03771
    DIO3 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    DIO3 Human Pre-designed siRNA Set A contains three designed siRNAs for DIO3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    DIO3 Human Pre-designed siRNA Set A
    DIO3 Human Pre-designed siRNA Set A
  • HY-129990
    Dios-Arg diTFA

    		Liposome Cancer
    Dios-Arg diTFA, a cationic lipid with an arginine-bearing headgroup, shows obvious double bond proton signals at around 5.2-5.3 ppm. Dios-Arg diTFA is used, coupled to DOPE, to bind siRNA and plasmid to for cationic LNPs for intracellular transport .
    Dios-Arg diTFA
  • HY-165674S
    11-dehydro-2,3-dinor Thromboxane B2-d9

    11-dehydo-2,3-dio TXB2-d9

    		 Isotope-Labeled Compounds Others
    11-dehydro-2,3-dinor Thromboxane B2-d9 (11-dehydo-2,3-dio TXB2-d9) is deuterium labeled 11-dehydro-2,3-dinor Thromboxane B2 .
    11-dehydro-2,3-dinor Thromboxane B2-d9
  • HY-165660S
    2,3-Dinor-6-ketoProstaglandinF1α-d9(sodium salt)

    2,3-Dio-6-ketoPGF1α-d9(sodium salt)

    		 Isotope-Labeled Compounds Others
    2,3-Dinor-6-ketoProstaglandinF1α-d9 (2,3-Dio-6-ketoPGF1α-d9) sodium saltis deuterium labeled 2,3-Dinor-6-ketoProstaglandinF1α(sodium salt) .
    2,3-Dinor-6-ketoProstaglandinF1α-d9(sodium salt)
  • HY-N3795
    Thiophene E

    Echinoynethiophene A; Thiophene A dio

    		 Others Others
    Thiophene E (Echinoynethiophene A) is a natural product .
    Thiophene E
  • HY-157718
    1,2-Di-O-(9Z-octadecenyl)-sn-glycero-3-phosphocholine

    		Biochemical Assay Reagents
    1,2-Di-O-(9Z-octadecenyl)-sn-glycero-3-phosphocholine is a surfactant that has the activity of promoting liposome formation. 1,2-Di-O-(9Z-octadecenyl)-sn-glycero-3-phosphocholine can effectively study the biological effects of ceramide and ceramide phosphate. 1,2-Di-O-(9Z-octadecenyl)-sn-glycero-3-phosphocholine shows important application in the determination of phospholipase A activity of lecithin-cholesterol acyltransferase in ether matrix.
    1,2-Di-O-(9Z-octadecenyl)-sn-glycero-3-phosphocholine
  • HY-W412313
    Methyl 3,5-di-O-(2,4-dichlorobenzyl)-D-ribofuranoside

    		Nucleoside Antimetabolite/Analog Others
    Methyl 3,5-di-O-(2,4-dichlorobenzyl)-D-ribofuranoside is a ribofuranose nucleoside analogue.
    Methyl 3,5-di-O-(2,4-dichlorobenzyl)-D-ribofuranoside
  • HY-138007
    SR-1903

    		ROR PPAR LXR Metabolic Disease Inflammation/Immunology
    SR-1903 is an inverse agonist of RORγ and PPARγ (IC50 of ∼100 nM and 209 nM for RORγ and PPARγ, respectively) and a LXR agonist. SR-1903 exhibits anti-inflammatory and anti-diabetic efficacy in collagen-induced arthritis and diet-induced obesity mouse models .
    SR-1903
  • HY-18341B
    L-Thyroxine sodium
    5+ Cited Publications

    Levothyroxine sodium; T4 sodium

    		 Thyroid Hormone Receptor Endogenous Metabolite Endocrinology Cancer
    L-Thyroxine sodium (Levothyroxine sodium) is a synthetic hormone for the research of hypothyroidism. DIO enzymes convert biologically active thyroid hormone (Triiodothyronine,T3) from L-Thyroxine (T4) .
    L-Thyroxine sodium
  • HY-147318
    PBENZ-DBRMD

    		Apoptosis Cancer
    PBENZ-DBRMD is a potent iodothyronine deiodinase type 3 (DIO3) inhibitor. PBENZ-DBRMD has anti-proliferative activity and induces apoptosis. PBENZ-DBRMD can be used for cancer research .
    PBENZ-DBRMD
  • HY-W010669
    L-Thyroxine sodium xhydrate
    5+ Cited Publications

    Sodium levothyroxine

    		 Thyroid Hormone Receptor Endocrinology
    L-Thyroxine sodium xhydrate (Levothyroxine; T4) is a synthetic hormone in the treatment of hypothyroidism. DIO enzymes convert biologically active hormone (Triiodothyronine,T3) from L-Thyroxine (T4).
    L-Thyroxine sodium xhydrate
  • HY-B0346
    Propylthiouracil
    3 Publications Verification

    6-n-Propylthiouracil; 6-Propyl-2-thiouracil; PTU

    		 Thyroid Hormone Receptor Endocrinology
    Propylthiouracil (6-n-Propylthiouracil), a thioamide antithyroid agent, is an orally active thyroperoxidase and type-1 deiodinase (DIO1) inhibitor. Propylthiouracil can be used for the Graves disease and hyperthyroidism research .
    Propylthiouracil
  • HY-18341
    L-Thyroxine
    5+ Cited Publications

    Levothyroxine; T4

    		 Thyroid Hormone Receptor Endogenous Metabolite Endocrinology Cancer
    L-Thyroxine (Levothyroxine; T4) is a synthetic hormone for the research of hypothyroidism. DIO enzymes convert biologically active thyroid hormone (Triiodothyronine,T3) from L-Thyroxine (T4) .
    L-Thyroxine
  • HY-18341A
    L-Thyroxine sodium salt pentahydrate
    5+ Cited Publications

    Sodium levothyroxine pentahydrate

    		 Thyroid Hormone Receptor Endogenous Metabolite Endocrinology Cancer
    L-Thyroxine sodium salt pentahydrate (Levothyroxine; T4) is a synthetic hormone for the research of hypothyroidism. DIO enzymes convert biologically active thyroid hormone (Triiodothyronine,T3) from L-Thyroxine (T4) .
    L-Thyroxine sodium salt pentahydrate
  • HY-P10032
    NN1177

    NNC9204-1177

    		 GCGR GLP Receptor Cytochrome P450 Metabolic Disease
    NN1177 is a long-acting GLP-1/glucagon receptor co-agonist. NN1177 can induce a dose-dependent body weight loss in diet-induced obese (DIO) mice .
    NN1177
  • HY-177297
    LCZ960

    NVP-LCZ960

    		 Glucokinase Metabolic Disease
    LCZ960 is an orally active glucokinase (GK) activator. LCZ960 stimulates GK activity in hepatocytes in vitro and stimulates glucose uptake in vivo through hepatic GK activation. LCZ960 lowers blood glucose in mice with diet-induced obesity (DIO). LCZ960 maintains normoglycemia and improves glucose tolerance in DIO mice and rats. LCZ960 stimulates glycogen synthase flux and increases hepatic glycogen turnover in rats. LCZ960 induces increased hepatic glycogen recycling. LCZ960 can be used to study high-fat diet-induced obesity and type 2 diabetes .
    LCZ960
  • HY-18341F
    Biotin-(L-Thyroxine)

    		Thyroid Hormone Receptor Endogenous Metabolite Endocrinology
    Biotin-(L-Thyroxine) is the biotinylated L-Thyroxine (HY-18341). L-Thyroxine is a synthetic hormone for the research of hypothyroidism. DIO enzymes convert biologically active thyroid hormone (Triiodothyronine,T3) from Biotin-(L-Thyroxine) (T4) .
    Biotin-(L-Thyroxine)
  • HY-111131
    RY764

    		Melanocortin Receptor Metabolic Disease
    RY746 is a selective MC4R agonist, with an EC50 of 10 nM. RY764 effectively inhibits food intake and reduces body weight gain in diet-induced obese (DIO) rat models. RY764 can be used for the study of obesity .
    RY764
  • HY-101699A
    AMG-076

    		MCHR1 (GPR24) Metabolic Disease
    AMG-076 is an orally bioavailable and selective MCHR1 antagonist. AMG-076 results in significant reduction in body weight gain in nonobese mice fed a high-fat diet and in high-fat diet-induced obese (DIO) mice .
    AMG-076
  • HY-P10032A
    NN1177 TFA

    NNC9204-1177 TFA

    		 GCGR Cytochrome P450 GLP Receptor Metabolic Disease
    NN1177 (NNC9204-1177) TFA is a long-acting GLP-1/glucagon receptor co-agonist. NN1177 TFA can induce a dose-dependent body weight loss in diet-induced obese (DIO) mice .
    NN1177 TFA
  • HY-B0346R
    Propylthiouracil (Standard)

    6-n-Propylthiouracil (Standard); 6-Propyl-2-thiouracil (Standard); PTU (Standard)

    		 Thyroid Hormone Receptor Reference Standards Endocrinology
    Propylthiouracil (Standard) is the analytical standard of Propylthiouracil. This product is intended for research and analytical applications. Propylthiouracil (6-n-Propylthiouracil), a thioamide antithyroid agent, is an orally active thyroperoxidase and type-1 deiodinase (DIO1) inhibitor. Propylthiouracil can be used for the Graves disease and hyperthyroidism research .
    Propylthiouracil (Standard)
  • HY-18341BR
    L-Thyroxine sodium (Standard)

    Levothyroxine sodium (Standard); T4 sodium (Standard)

    		 Reference Standards Thyroid Hormone Receptor Endogenous Metabolite Endocrinology Cancer
    L-Thyroxine (sodium) (Standard) is the analytical standard of L-Thyroxine (sodium). This product is intended for research and analytical applications. L-Thyroxine sodium (Levothyroxine sodium) is a synthetic hormone for the research of hypothyroidism. DIO enzymes convert biologically active thyroid hormone (Triiodothyronine,T3) from L-Thyroxine (T4) .
    L-Thyroxine sodium (Standard)
  • HY-18341S1
    Thyroxine hydrochloride-13C6

    Levothyroxine-13C6; T4-13C6

    		 Isotope-Labeled Compounds Thyroid Hormone Receptor Endogenous Metabolite Endocrinology
    Thyroxine hydrochloride- 13C6 is the 13C-labeled L-Thyroxine. L-Thyroxine (Levothyroxine; T4) is a synthetic hormone for the research of hypothyroidism. DIO enzymes convert biologically active thyroid hormone (Triiodothyronine,T3) from L-Thyroxine (T4) .
    Thyroxine hydrochloride-13C6
  • HY-101699
    AMG-076 free base

    		MCHR1 (GPR24) Metabolic Disease
    AMG-076 free base is an orally bioavailable and selective MCHR1 antagonist. AMG-076 free base results in significant reduction in body weight gain in nonobese mice fed a high-fat diet and in high-fat diet-induced obese (DIO) mice .
    AMG-076 free base
  • HY-18341S2
    L-Thyroxine-13C6

    		Thyroid Hormone Receptor Endogenous Metabolite Endocrinology
    L-Thyroxine- 13C6 is the 13C labeled L-Thyroxine . L-Thyroxine (Levothyroxine;T4) is a synthetic hormone for the research of hypothyroidism. DIO enzymes convert biologically active thyroid hormone (Triiodothyronine,T3) from L-Thyroxine (T4) .
    L-Thyroxine-13C6
  • HY-18341R
    L-Thyroxine (Standard)

    Levothyroxine (Standard); T4 (Standard)

    		 Reference Standards Thyroid Hormone Receptor Endogenous Metabolite Endocrinology Cancer
    L-Thyroxine (Standard) is the analytical standard of L-Thyroxine. This product is intended for research and analytical applications. L-Thyroxine (Levothyroxine; T4) is a synthetic hormone for the research of hypothyroidism. DIO enzymes convert biologically active thyroid hormone (Triiodothyronine,T3) from L-Thyroxine (T4) .
    L-Thyroxine (Standard)
  • HY-W010669R
    L-Thyroxine sodium xhydrate (Standard)

    Sodium levothyroxine (Standard)

    		 Reference Standards Thyroid Hormone Receptor Endocrinology
    L-Thyroxine sodium xhydrate (Standard) is the analytical standard of L-Thyroxine sodium xhydrate. This product is intended for research and analytical applications. L-Thyroxine sodium xhydrate (Levothyroxine; T4) is a synthetic hormone in the treatment of hypothyroidism. DIO enzymes convert biologically active hormone (Triiodothyronine,T3) from L-Thyroxine (T4).
    L-Thyroxine sodium xhydrate (Standard)
  • HY-18341AR
    L-Thyroxine sodium salt pentahydrate (Standard)

    		Thyroid Hormone Receptor Endogenous Metabolite Endocrinology Cancer
    L-Thyroxine (sodium salt pentahydrate) (Standard) is the analytical standard of L-Thyroxine (sodium salt pentahydrate). This product is intended for research and analytical applications. L-Thyroxine sodium salt pentahydrate (Levothyroxine; T4) is a synthetic hormone for the research of hypothyroidism. DIO enzymes convert biologically active thyroid hormone (Triiodothyronine,T3) from L-Thyroxine (T4) .
    L-Thyroxine sodium salt pentahydrate (Standard)
  • HY-133876
    4-Di-16-ASP

    DiA

    		 Fluorescent Dye Others
    4-Di-16-ASP is a green fluorescent membrane dye. 4-Di-16-ASP is a lipophilic aminostyryl probe with a broad emission spectrum (can be detected with green, orange or even red filters). It is commonly used for neuronal membrane tracing (it diffuses faster than DiO) .
    4-Di-16-ASP
  • HY-151959
    FXR agonist 4

    		FXR Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    FXR agonist 4 (compound 10a) is an agonist of farnesoid X receptor (FXR) with an EC50 value of 1.05 μM. FXR agonist 4 effectively improves hyperlipidemia, hepatic steatosis, insulin resistance and hepatic inflammation in DIO mice. FXR agonist 4 can be used for the research of non-alcoholic fatty liver disease (NAFLD) .
    FXR agonist 4
  • HY-144287
    Glucokinase activator 3

    		Glucokinase Sodium Channel Metabolic Disease
    Glucokinase activator 3 is an orally active Glucokinase (GK) activator with an AC50 of 38 nM. Glucokinase activator 3 inhibits hERG channel and sodium channel in patch clamp assays. Glucokinase activator 3 exhibits high efficacy in reducing blood glucose in diet-induced obese (DIO) mice. Glucokinase activator 3 has the potential for the research of type 2 diabetes .
    Glucokinase activator 3
  • HY-147927
    Human enteropeptidase-IN-1

    		Enteropeptidase Metabolic Disease
    Human enteropeptidase-IN-1 (compound 6b) is a highly potent, orally active and low systemic exposure enteropeptidase inhibitor. Human enteropeptidase-IN-1 boosts the increase in fecal protein output, and exhibits potent body weight loss in diet-induced obese (DIO) rat model. Human enteropeptidase-IN-1 can be used for anti-obesity research .
    Human enteropeptidase-IN-1
  • HY-14342
    MK-5046
    2 Publications Verification

    		 Bombesin Receptor Metabolic Disease
    MK-5046 is a potent, selective and orally active Bombesin receptor subtype-3 (BRS-3) allosteric agonist with an IC50 and an EC50 value of 27 and 25 nM for hBRS-3, respectively. MK-5046 inhibits food intake and reduces body weight of diet-induced obese (DIO) mouse models. MK-5046 can be used for the research of obesity .
    MK-5046
  • HY-P11321
    IUB0271

    acyl-GIP

    		 Insulin Receptor Metabolic Disease
    IUB0271 (acyl-GIP) is a fatty acylated and long-acting glucose-dependent insulinotropic polypeptide (GIP). IUB0271 increases cFos neuronal activity in hypothalamic feeding centers and decreases body weight, food intake and glycemia in DIO mouse models, and these effects depend on CNS-GIPR signaling. IUB0271 can be used for type 2 diabetes mellitus (T2DM) and obesity research .
    IUB0271
  • HY-178857
    CB1 antagonist 6

    		Cannabinoid Receptor Metabolic Disease
    CB1 antagonist 6 (Compound 11jE2) is an orally active CB1R antagonist, with an IC50 value of 23 nM. CB1 antagonist 6 significantly reduces food intake and body weight, improves glucose tolerance and insulin resistance, and decreases serum ALT and AST levels in diet-induced obese (DIO) mice, demonstrating hepatoprotective effects. CB1 antagonist 6 can be used for the study of metabolic syndrome (obesity, diabetes) .
    CB1 antagonist 6
  • HY-18341S4
    L-Thyroxine-13C6-1

    Levothyroxine-13C6-1; T4-13C6-1

    		 Isotope-Labeled Compounds Endogenous Metabolite Thyroid Hormone Receptor Endocrinology
    L-Thyroxine- 13C6-1 (Levothyroxine- 13C6-1; T4- 13C6-1) is a 13C labeled L-Thyroxine (HY-18341). L-Thyroxine (Levothyroxine; T4) is a synthetic hormone for the research of hypothyroidism. DIO enzymes convert biologically active thyroid hormone (Triiodothyronine,T3) from L-Thyroxine (T4) .
    L-Thyroxine-13C6-1
  • HY-160912
    ELOVL6-IN-5

    		ELOVL Cancer
    ELOVL6-IN-5 (compound B) is an inhibitor of the elongase enzyme of long-chain fatty acid family 6 (ELOVL6). ELOVL6 is a rate-limiting enzyme for the elongation of saturated and monounsaturated long-chain fatty acids and is an effective target for inhibiting diabetes. ELOVL6-IN-5 reduces hepatic fatty acid levels in a mouse model of diet-induced obesity (DIO). However, ELOVL6 inhibition by ELOVL6-IN-5 did not improve insulin resistance .
    ELOVL6-IN-5
  • HY-14342A
    (R)-MK-5046

    		Bombesin Receptor Metabolic Disease
    (R)-MK-5046 is the isomer of MK-5046 (HY-14342), and can be used as an experimental control. MK-5046 is a potent, selective and orally active Bombesin receptor subtype-3 (BRS-3) allosteric agonist with an IC50 and an EC50 value of 27 and 25 nM for hBRS-3, respectively. MK-5046 inhibits food intake and reduces body weight of diet-induced obese (DIO) mouse models. MK-5046 can be used for the research of obesity .
    (R)-MK-5046
  • HY-147927A
    (S)-Human enteropeptidase-IN-1

    		Enteropeptidase Metabolic Disease
    (S)-Human enteropeptidase-IN-1 (Compound 6c) is an orally active enteropeptidase inhibitor with low systemic exposure (IC50 (initial): 26 nM; IC50 (app): 1.8 nM). (S)-Human enteropeptidase-IN-1 promotes increased fecal protein output and effectively reduces body weight in a diet-induced obese (DIO) rat model. (S)-Human enteropeptidase-IN-1 inhibits enteropeptidase via a reversible covalent mechanism and prolongs the enzyme inactivation time. (S)-Human enteropeptidase-IN-1 can be used in anti-obesity research .
    (S)-Human enteropeptidase-IN-1
  • HY-12443
    PF-5006739

    		Casein Kinase Neurological Disease
    PF-5006739 is a potent and selective inhibitor of CK1δ/ε with IC50s of 3.9 nM and 17.0 nM, respectively. PF-5006739 is a potential therapeutic agent for a range of psychiatric disorders with low nanomolar in vitro potency for CK1δ/ε and high kinome selectivity. PF-5006739 attenuats opioid agent-seeking behavior in a rodent operant reinstatement model in animals in a dose-dependent manner . PF-5006739 improves glucose tolerance in both diet-induced obesity (DIO) and genetic (ob/ob) mice models of obesity .
    PF-5006739
  • HY-172661
    Kylo-0603

    		Thyroid Hormone Receptor Interleukin Related LDLR Infection Metabolic Disease
    KYLO-0603 is an orally active, selective THR-β agonist (EC50: 31.07 nM). KYLO-0603 has significant activity in lowering serum cholesterol and low-density lipoprotein cholesterol. KYLO-0603 upregulates the expression of THR-regulated genes (including iodothyronine deiodinase 1 (Dio1), malic enzyme 1 (Me1), and thyroid hormone response (Thrsp) gene) and inhibits the expression of inflammatory and fibrotic genes (low-density lipoprotein receptor (LDL-R) gene) by activating THR-β receptors. KYLO-0603 can be used to treat metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis research .
    Kylo-0603
  • HY-114340
    LEM-14

    		Histone Methyltransferase Apoptosis Cancer
    LEM-14 is a potent and selective NSD2 inhibitor with an IC50 of 132 µM. LEM-14 has very weak activitv against NSD1 and has no activity against NSD3. LEM-14 inhibits fibrotic gene expression in ND but not DIO BMDMs. LEM-14 combined with ionizing radiation (IR) enhances the apoptosis rate and reduces the colony-formation ability of CRC cells. LEM-14 exhibits enhanced anti-tumor efficacy in Balb/c nude mice bearing LoVo cell xenografts when combined with ionizing radiation. LEM-14 has the potential for the research of multiple myeloma and colorectal cancer .
    LEM-14
  • HY-123765
    JTT-553

    		Acyltransferase Metabolic Disease
    JTT-553 is a DGAT1 inhibitor (IC50: 2.38 nM). JTT-553 reduces plasma concentrations of glucose, insulin, non-esterified fatty acids (NEFA), total cholesterol (TC), and hepatic triglycerides (TG). JTT-553 improves insulin-dependent glucose uptake and glucose intolerance in adipose tissue of DIO mice. JTT-553 reduces TNF-α mRNA levels and increases GLUT4 mRNA levels in adipose tissue of KK-Ay mice. JTT-553 improves adipose tissue insulin resistance and systemic glucose metabolism by reducing body weight. JTT-553 can be used in the study of obesity and type 2 diabetes mellitus (T2DM) .
    JTT-553
  • HY-P11075
    [Lys5,Tyr6,mLeu9,Nle10]-Neurokinin A (4-10)

    		Neurokinin Receptor Metabolic Disease
    [Lys5,Tyr6,mLeu9,Nle10]-Neurokinin A (4-10) (ID 305) is a selective NK2R agonist with an EC50 of 3.7  nM for hNK2R. [Lys5,Tyr6,mLeu9,Nle10]-Neurokinin A (4-10) significantly inhibits weight loss in diet-induced obese (DIO) mice model and improves Loperamide (HY-156131)-induced dysfunctional voiding in wild-type mice. [Lys5,Tyr6,mLeu9,Nle10]-Neurokinin A (4-10) can be used for neurokinin receptor mediated disorders, such as obesity, insulin resistance and type 2 diabetes research .
    [Lys5,Tyr6,mLeu9,Nle10]-Neurokinin A (4-10)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: